Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Tumor-infiltrating lymphocytes (TIL)
Email alerts
Tumor-infiltrating lymphocytes (TIL)
Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
Qin
Tan
,
Chaoting
Zhang
,
Wenjun
Yang
,
Ying
Liu
,
Palashati
Heyilimu
,
Dongdong
Feng
,
Liying
Xing
,
Yang
Ke
,
Zheming
Lu
Journal for ImmunoTherapy of Cancer
Dec 2019,
7
(1)
232;
DOI:
10.1186/s40425-019-0709-7
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
Zipei
Feng
,
Sachin
Puri
,
Tarsem
Moudgil
,
William
Wood
,
Clifford C.
Hoyt
,
Chichung
Wang
,
Walter J.
Urba
,
Brendan D.
Curti
,
Carlo B.
Bifulco
,
Bernard A.
Fox
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(1)
47;
DOI:
10.1186/s40425-015-0091-z
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(538)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(942)
Commentary/Editorials
(142)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(55)
Guidelines and Consensus Statements
(50)
Imaging and Immunotherapy
(8)
Immune Cell Therapies and Immune Cell Engineering
(214)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(409)
Liquid Biopsies
(9)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(144)
Reviews
(239)
Open access
(4879)
Press releases
